Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.77 CHF | +0.79% | +1.41% | +17.33% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.33% | 15.07B | |
+19.96% | 43.03B | |
+23.86% | 22.7B | |
+23.91% | 14.77B | |
+57.46% | 13.05B | |
-0.05% | 6.79B | |
-14.19% | 6.58B | |
-8.87% | 5.73B | |
+13.42% | 5.5B | |
+5.66% | 4.59B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Sandoz Group Logs Growth in Q1 Net Sales, Affirms FY24 Outlook